Sort   by:  
 Page size 
UnknownA Phase Ib Study of Single-Agent Idelalisib Followed by Idelalisib in Combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
Not available
S-EPMC7648342 | biostudies-literature
UnknownPhase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma.
Not available
S-EPMC4612326 | biostudies-literature
UnknownRandomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513.
Not available
S-EPMC8639715 | biostudies-literature
UnknownTreatment patterns and outcomes in pancreatic cancer: Retrospective claims analysis.
Not available
S-EPMC7221424 | biostudies-literature
UnknownA Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer.
Not available
S-EPMC7496218 | biostudies-literature
UnknownClinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conventional irinotecan-based chemotherapy: a real-world study.
Not available
S-EPMC10494436 | biostudies-literature
UnknownWEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner.
Not available
S-EPMC5018859 | biostudies-literature
UnknownA Phase 1b study of the OxPhos inhibitor ME-344 with bevacizumab in refractory metastatic colorectal cancer.
Not available
S-EPMC11868331 | biostudies-literature
UnknownTargeting BARD1 suppresses a Myc-dependent transcriptional program and tumor growth in pancreatic ductal adenocarcinoma.
Not available
S-EPMC11957605 | biostudies-literature
UnknownA phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies.
Not available
S-EPMC7957175 | biostudies-literature
Sort   by:  
 Page size